2005 IPO

Avalon Pharmaceuticals Stock

As of May 28, 2009, Avalon Pharmaceuticals, Inc. was acquired by Clinical Data, Inc. Avalon Pharmaceuticals, Inc., a biopharmaceutical

Sign up today and learn more about Avalon Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Avalon Pharmaceuticals Stock

As of May 28, 2009, Avalon Pharmaceuticals, Inc. was acquired by Clinical Data, Inc. Avalon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cancer therapeutics using its proprietary AvalonRx technology in the United States. The company’s lead product candidate, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase IIa clinical development for the treatment of hematologic and solid cancers. Avalon Pharmaceuticals has drug discovery, development, and commercialization agreement with Merck & Co., Inc. to identify and develop inhibitors against a selected target in the area of oncology; a collaboration and license agreement with MedImmune, Inc. for the discovery of small molecule therapeutic compounds in the area of inflammatory disease; a collaboration agreement with ChemDiv, Inc. for the discovery and development of small molecule oncology therapeutics; a collaboration with Medarex, Inc. to jointly research, develop, and commercialize human antibodies against the company’s cancer targets; and an agreement with Novartis Institutes for Biomedical Research, Inc. for the discovery of small molecule therapeutic compounds. The company was incorporated in 1999 and is headquartered in Germantown, Maryland.

Funding History

December 2001$70.0M
October 2008$237K

Management

Member of the Board of Directors

William Scott

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo